Holen Sie sich die Stockscreener-App
1.15
0.88%
0.01
Vorhandelsmarkt:
1.19
0.04
+3.48%
Sonoma Pharmaceuticals Inc Aktie (SNOA) Neueste Nachrichten
Sonoma Pharmaceuticals Inc (SNOA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Sonoma Pharmaceuticals Inc - TradingKey
SNOA|Sonoma Pharmaceuticals Inc|Price:1.140|Chg%:-0.020 - TradingKey
TradingKey - TradingKey
Sonoma Pharmaceuticals Inc (SNOA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
19,898 Common Stock of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 24-JUL-2026. - marketscreener.com
Sonoma Pharmaceuticals (SNOA) Edges Higher as Volume Patterns Suggest Accumulation Near Key SupportAAII Bearish - dars.gov.et
Sonoma Pharmaceuticals (SNOA) Slips 4.21% as Stock Tests Key Support LevelsNAAIM Leverage - dars.gov.et
Sonoma Pharmaceuticals (SNOA) Holds Steady at $1.26 as Consolidation ContinuesInside Day Breakout - dars.gov.et
Enterprise value to revenue forward of Sonoma Pharmaceuticals, Inc. – NASDAQ:SNOA - TradingView
Form 4 Sonoma Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa
Price to sales forward of Sonoma Pharmaceuticals, Inc. – NASDAQ:SNOA - TradingView
Sonoma Pharmaceuticals (NASDAQ: SNOA) awards CEO 10,000 RSUs in equity grant - Stock Titan
Enterprise value to EBIT forward of Sonoma Pharmaceuticals, Inc. – NASDAQ:SNOA - TradingView
Price to book forward of Sonoma Pharmaceuticals, Inc. – FWB:O8Z - TradingView
Price to sales forward of Sonoma Pharmaceuticals, Inc. – FWB:O8Z - TradingView
SNOA Should I Buy - Intellectia AI
Sonoma Pharmaceuticals (SNOA) Secures FDA Clearance for Microdac - GuruFocus
Sonoma Pharmaceuticals receives FDA clearance for wound solution - Investing.com
Sonoma Pharmaceuticals receives FDA clearance for wound solution By Investing.com - Investing.com Canada
Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution - ACCESS Newswire
Sonoma Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SNOA) - TradingView
Sonoma Pharmaceuticals Inc (SNOA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Sonoma Pharmaceuticals Inc (SNOA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Sonoma Pharmaceuticals Expands At-the-Market Equity Offering Capacity - The Globe and Mail
Sonoma Pharmaceuticals Files 8-K for $3.6 Million Common Stock Offering – Nasdaq: SNOA, June 2026 - Minichart
According to a recent filing submitted to the U.S. Securities and Exchange Commission (SEC), Sonoma Pharmaceuticals, Inc. has raised the maximum total offering price of its common stock issuance to $3.64 million. - Bitget
Sonoma Pharmaceuticals increases at-the-market offering to $3.64 million - Investing.com UK
Sonoma Pharmaceuticals increases at-the-market offering to $3.64 million By Investing.com - Investing.com Nigeria
Sonoma Pharmaceuticals boosts shelf offering capacity to $3.64M after prior $574.6K sales - TradingView
[8-K] Sonoma Pharmaceuticals, Inc. Reports Material Event - Stock Titan
Sonoma Pharmaceuticals Inc (SNOA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sonoma Pharmaceuticals Inc (SNOA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Sonoma Pharmaceuticals Inc (SNOA) Institutional Confidence - TradingKey
Sonoma Pharmaceuticals Q4 revenue rises 48% on US growth - TradingView
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results - ACCESS Newswire
BRIEF-Sonoma Pharmaceuticals Q4 Net Income USD -600 Thousand - TradingView
Sonoma Pharmaceuticals, Inc. FY 2026: Revenue $19.5M, EPS $(1.89) — 10-K Summary - TradingView
Sonoma Pharmaceuticals | 10-K: FY2026 Annual Report - Moomoo
Sonoma Pharmaceuticals (NASDAQ: SNOA) outlines global HOCl strategy and risks - Stock Titan
SNOA Q1 2026 Earnings: EPS Misses Estimates Amid Operational and Revenue Disclosures - newsline.com
Sonoma Pharmaceuticals Q1 2026 Earnings: EPS Miss Triggers Sharp SelloffCFO Commentary Report - newsline.com
Sonoma Pharmaceuticals Inc. (SNOA) Q1 2026 Earnings: EPS Falls Short of Estimates, Stock Unchanged - newsline.com
Sonoma Pharmaceuticals (SNOA) Edges Higher, Holds Within Established Trading RangeAAII Bearish - dars.gov.et
SNOA Q1 2026 Earnings: EPS Misses Estimates, Stock Rises 2.7%Dividend Cut Risk - dars.gov.et
SNOASonoma Pharmaceuticals Inc Stock Price and Quote - Finviz
Sonoma Pharmaceuticals (SNOA) Edges Higher, Testing Resistance at $1.13Channel Breakout - The Legal Advocate
Sonoma Pharmaceuticals Inc. (SNOA) Q1 2026 Earnings: EPS Slightly Misses Estimates Amid Thin Revenue DisclosuresOne-Time Gain Impact - newsline.com
Sonoma Pharmaceuticals (SNOA) Edges Higher, Testing Key Resistance at $1.13Volatility Smirk - Newser
SNOA SEC FilingsSonoma Pharmaceu 10-K, 10-Q, 8-K Forms - Stock Titan
0.30%
2.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):